SI
VIRX

Sofinnova Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Sofinnova Investments’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-32,398
Closed -$816K – 74
2019
Q3 		$816K Buy
+32,398
New +$935K 0.07% 69

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Sofinnova Investments's VIRX Position: Q4 2019 in Review

Sofinnova Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 32,398 shares — an estimated $816K sold.

Sofinnova Investments first reported a position in VIRX in Q3 2019 and held it in 1 quarter. The position peaked at $816K in Q3 2019. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • Sofinnova Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Sofinnova Investments sold 32,398 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $816K.
  • Sofinnova Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Sofinnova Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $816K in Q3 2019.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Sofinnova Investments's 13F filing for Q4 2019, filed 14 Feb 2020.